sp taking another bashing, page-10

The reference re "wiped out" by the ACL poster may be hyperbolic in the case of CXS, but it was just making the point that formative biotechs can be a risk. If not "wiped out", dropping from $0.70 to a low of $0.265 in 24hrs was obviously not a pleasant experience for CXS holders.

The CXS experience has some relevance to ACL, since both are navigating through FDA processes and dependent on approval.

There was much HC discussion about CXS risks prior to the FDA meeting. It was too risky for me at the time. In my mind CXS is a lower risk now at the lower SP and having a better understanding of FDA concerns. As biotek says, the problem now is open-ended timeframe.